Concepedia

Eric Assenat

EA

3

Publications

830

Citations

3

H-Index

2017

Active since

Affiliations

Inserm(Current)

Hôpital Beaujon

Centre Hospitalier Universitaire de Montpellier

Université Grenoble Alpes

Université de Poitiers

Eric Assenat is an author at Inserm specializing in hepatocellular carcinoma, medicine, and hepatology.

Top concepts

Publications per year

2017–2024

3

Publications

3

Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial

Valérie Vilgrain, Héléna Pereira, Eric Assenat et al. · The Lancet Oncology · 2017 · 794 citations

, , +10

Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trial

Philippe Merle, Jean‐Frédéric Blanc, Julien Edeline et al. · Digestive and Liver Disease · 2023 · 20 citations · Full text

, , +8

Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies

Alessandro Parisi, Blandine Delaunay, Giada Pinterpe et al. · European Journal of Cancer · 2024 · 16 citations · Full text

Rows per page

1–3 of 3